Dios Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 24-10-2024
- Paid Up Capital ₹ 1.91 M
as on 24-10-2024
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.30 M
as on 24-10-2024
- Revenue 1.29%
(FY 2023)
- Profit -155.32%
(FY 2023)
- Ebitda -12.39%
(FY 2023)
- Net Worth -3.45%
(FY 2023)
- Total Assets -15.10%
(FY 2023)
About Dios Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.91 M.
The company currently has active open charges totaling ₹9.30 M.
Gagan Taneja, Jai Chabra, Geeta Arora, and One other member serve as directors at the Company.
- CIN/LLPIN
U51397DL2011PTC223012
- Company No.
223012
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Dios Lifesciences Private Limited offer?
Dios Lifesciences Private Limited offers a wide range of products and services, including Vitamins & Supplements, Mineral Supplements.
Who are the key members and board of directors at Dios Lifesciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gagan Taneja  | Director | 29-Jul-2011 | Current |
| Jai Chabra | Director | 29-Jul-2011 | Current |
| Geeta Arora | Director | 22-May-2023 | Current |
| Manish Srivastava | Director | 30-May-2022 | Current |
Financial Performance of Dios Lifesciences.
Dios Lifesciences Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.29% increase. The company also saw a substantial fall in profitability, with a 155.32% decrease in profit. The company's net worth dipped by a decrease of 3.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dios Lifesciences?
In 2023, Dios Lifesciences had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 31 Aug 2023 | ₹3.10 M | Open |
Hdfc Bank Limited Creation Date: 31 Aug 2023 | ₹3.10 M | Open |
Hdfc Bank Limited Creation Date: 21 Aug 2023 | ₹3.10 M | Open |
How Many Employees Work at Dios Lifesciences?
Dios Lifesciences has a workforce of 85 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dios Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dios Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
